

Juan Martin-Liberal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8403227/publications.pdf>

Version: 2024-02-01

33
papers

990
citations

687363

13
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

1945
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	10.7	193
2	Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 765-767.	4.2	129
3	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	3.7	127
4	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86.	7.7	100
5	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	1.3	54
6	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	7.3	54
7	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	2.8	53
8	Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. <i>Clinical Sarcoma Research</i> , 2013, 3, 13.	2.3	32
9	Safety of pembrolizumab for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 957-964.	2.4	27
10	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	3.6	22
11	Leiomyosarcoma: Principles of management. <i>Intractable and Rare Diseases Research</i> , 2013, 2, 127-9.	0.9	19
12	Prospects for MEK inhibitors for treating cancer. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 483-495.	2.4	17
13	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> , 2018, 19, 505.	1.6	17
14	Vemurafenib for the treatment of <i>BRAF</i> mutant metastatic melanoma. <i>Future Oncology</i> , 2015, 11, 579-589.	2.4	16
15	New RAF kinase inhibitors in cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1235-1245.	1.8	13
16	First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. <i>Clinical Sarcoma Research</i> , 2015, 5, 10.	2.3	13
17	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1235-1243.	6.4	12
18	A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate. <i>Journal of Clinical Oncology</i> , 2017, 35, 2570-2570.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Expert Opinion on Drug Safety, 2013, 12, 905-911.	2.4	11
20	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	3.6	8
21	INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3113-TPS3113.	1.6	8
22	Antiangiogenic approach in soft-tissue sarcomas. Expert Review of Anticancer Therapy, 2013, 13, 975-982.	2.4	7
23	New drugs in sarcomas. Expert Opinion on Pharmacotherapy, 2014, 15, 221-229.	1.8	7
24	Encorafenib plus binimetinib: an embarrassment of riches. Lancet Oncology, The, 2018, 19, 1263-1264.	10.7	7
25	Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Expert Opinion on Investigational Drugs, 2019, 28, 39-50.	4.1	7
26	Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors – A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunology, Immunotherapy, 2016, 65, 769-770.	4.2	6
27	Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?. Expert Review of Anticancer Therapy, 2015, 15, 257-259.	2.4	5
28	Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. Oncogene, 2021, 40, 5042-5048.	5.9	2
29	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.. Journal of Clinical Oncology, 2014, 32, 10551-10551.	1.6	2
30	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	2.8	1
31	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma.. Journal of Clinical Oncology, 2015, 33, e21516-e21516.	1.6	0
32	Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.. Journal of Clinical Oncology, 2022, 40, 2581-2581.	1.6	0
33	Analysis of phase I clinical trials (Ph1-CT) new enrollment patterns in the immuno-oncology era.. Journal of Clinical Oncology, 2022, 40, e14549-e14549.	1.6	0